{"id":51864,"date":"2025-12-23T21:08:06","date_gmt":"2025-12-23T13:08:06","guid":{"rendered":"https:\/\/flcube.com\/?p=51864"},"modified":"2025-12-23T21:08:07","modified_gmt":"2025-12-23T13:08:07","slug":"coherent-biopharma-licenses-pdc-cbp-1018-to-multivalent-in-2-billion-prostate-cancer-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=51864","title":{"rendered":"Coherent Biopharma Licenses PDC CBP-1018 to MultiValent in $2\u202fBillion Prostate Cancer Deal"},"content":{"rendered":"\n

Coherent Biopharma<\/strong> announced an exclusive licensing agreement with MultiValent Biotherapies, Inc.<\/strong> for CBP\u20111018<\/strong>, a bispecific peptide\u2011drug conjugate (PDC)<\/strong> targeting prostate cancer. MultiValent gains global rights (ex\u2011Greater China) for the asset, with Coherent receiving USD\u202f20\u202fmillion upfront<\/strong>, a 20% equity stake<\/strong> in MultiValent, up to $2\u202fbillion in milestones<\/strong>, and tiered royalties.<\/p>\n\n\n\n

Transaction Structure<\/h2>\n\n\n\n
Component<\/th>Details<\/th><\/tr><\/thead>
Asset Licensed<\/strong><\/td>CBP\u20111018 (bispecific PDC targeting PSMA and FR\u03b1)<\/td><\/tr>
Platform<\/strong><\/td>Bi\u2011XDC (Bispecific Dual\u2011Ligand Conjugate)<\/td><\/tr>
Payload<\/strong><\/td>Auristatin\u2011E<\/td><\/tr>
Territory<\/strong><\/td>Global (excluding Greater China)<\/td><\/tr>
Upfront Payment<\/strong><\/td>USD\u202f20\u202fmillion cash<\/td><\/tr>
Equity Stake<\/strong><\/td>20% ownership in MultiValent<\/td><\/tr>
Milestone Payments<\/strong><\/td>Up to USD\u202f2\u202fbillion<\/strong> (development, regulatory, commercial)<\/td><\/tr>
Royalties<\/strong><\/td>Tiered royalties on net sales<\/td><\/tr>
Indication<\/strong><\/td>Prostate cancer (focal therapy development)<\/td><\/tr>
Development Plan<\/strong><\/td>Phase\u202fI initiation planned for 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile & Differentiation<\/h2>\n\n\n\n
Attribute<\/th>CBP\u20111018<\/th>Competitive Context<\/th><\/tr><\/thead>
Targets<\/strong><\/td>PSMA and FR\u03b1 (bispecific)<\/td>Dual targeting of validated prostate cancer antigens<\/td><\/tr>
Modality<\/strong><\/td>Peptide\u2011drug conjugate (PDC)<\/td>Emerging alternative to ADCs; improved tumor penetration<\/td><\/tr>
Payload<\/strong><\/td>Auristatin\u2011E (microtubule inhibitor)<\/td>Potent cytotoxic agent<\/td><\/tr>
Mechanism<\/strong><\/td>Bispecific peptide binding \u2192 endocytosis \u2192 payload release<\/td>Targets both tumor cells and CAFs<\/td><\/tr>
Innovation<\/strong><\/td>First bispecific PDC<\/strong> for prostate cancer from China<\/td>Novel Bi\u2011XDC platform<\/td><\/tr>
Potential<\/strong><\/td>Focal therapy alternative to surgery\/radiation\/ADT<\/td>Addresses unmet need for localized treatment<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Opportunity<\/h2>\n\n\n\n
Metric<\/th>Value<\/th>Context<\/th><\/tr><\/thead>
Global Prostate Cancer Market<\/strong><\/td>$12\u201115\u202fbillion<\/strong> (2025)<\/td>Second most common cancer in men<\/td><\/tr>
PSMA\u2011Targeted Therapy Market<\/strong><\/td>$2\u20113\u202fbillion<\/strong> (including diagnostics and therapeutics)<\/td>Growing with approvals like Pluvicto<\/td><\/tr>
Focal Therapy Segment<\/strong><\/td>$500\u2011800\u202fmillion<\/strong> (potential)<\/td>Minimally invasive alternatives to radical treatment<\/td><\/tr>
CBP\u20111018 Peak Sales Potential<\/strong><\/td>$300\u2011500\u202fmillion<\/strong> (global estimate)<\/td>10\u201115% share if approved in focal therapy<\/td><\/tr>
Competitive Advantage<\/strong><\/td>Bispecific targeting<\/strong> and PDC modality<\/strong><\/td>Differentiated from monospecific ADCs<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Implications<\/h2>\n\n\n\n